This clinical trial focuses on patients with early Alzheimer Disease, a progressive brain disorder that affects memory and thinking skills. The study evaluates a new treatment approach using aldesleukin (also known as ILT-101), which is a type of protein that can influence the immune system. The medication will be administered through cutaneous (skin) injections along with sodium chloride solution.

The purpose of this research is to determine if this treatment can slow down the progression of Alzheimer Disease compared to placebo over an 18-month period. The study involves regular treatment visits where participants receive either the study medication or placebo through skin injections. The treatment period lasts for 21 days, during which patients receive carefully controlled doses of the medication.

During the study, participants will be monitored by healthcare professionals to track changes in their condition. The treatment involves the use of Proleukin, which contains the active substance aldesleukin, administered as an injectable solution. Participants will need to attend multiple clinic visits throughout the study period for treatment administration and evaluation of their condition.